ID   2AAA_HUMAN              Reviewed;         589 AA.
AC   P30153; Q13773; Q6ICQ3; Q96DH3;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 4.
DT   10-MAY-2017, entry version 181.
DE   RecName: Full=Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform;
DE   AltName: Full=Medium tumor antigen-associated 61 kDa protein;
DE   AltName: Full=PP2A subunit A isoform PR65-alpha;
DE   AltName: Full=PP2A subunit A isoform R1-alpha;
GN   Name=PPP2R1A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 242-255.
RC   TISSUE=Placenta;
RX   PubMed=2554323; DOI=10.1073/pnas.86.22.8669;
RA   Walter G., Ferre F., Espiritu O., Carbone-Wiley A.;
RT   "Molecular cloning and sequence of cDNA encoding polyoma medium tumor
RT   antigen-associated 61-kDa protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:8669-8672(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2159327; DOI=10.1021/bi00465a002;
RA   Hemmings B.A., Adams-Pearson C., Maurer F., Mueller P., Goris J.,
RA   Merlevede W., Hofsteenge J., Stone S.R.;
RT   "Alpha- and beta-forms of the 65-kDa subunit of protein phosphatase 2A
RT   have a similar 39 amino acid repeating structure.";
RL   Biochemistry 29:3166-3173(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 34-46, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, and Cajal-Retzius cell;
RA   Lubec G., Vishwanath V.;
RL   Submitted (MAR-2007) to UniProtKB.
RN   [6]
RP   PROTEIN SEQUENCE OF 204-214; 261-272 AND 521-527.
RX   PubMed=8694763; DOI=10.1042/bj3170187;
RA   Zolnierowicz S., van Hoof C., Andjelkovic N., Cron P., Stevens I.,
RA   Merlevede W., Goris J., Hemmings B.A.;
RT   "The variable subunit associated with protein phosphatase 2A0 defines
RT   a novel multimember family of regulatory subunits.";
RL   Biochem. J. 317:187-194(1996).
RN   [7]
RP   BINDING DOMAINS.
RX   PubMed=8254721;
RA   Ruediger R., Hentz M., Fait J., Mumby M., Walter G.;
RT   "Molecular model of the A subunit of protein phosphatase 2A:
RT   interaction with other subunits and tumor antigens.";
RL   J. Virol. 68:123-129(1994).
RN   [8]
RP   INTERACTION WITH IPO9.
RX   PubMed=12670497; DOI=10.1016/S0006-291X(03)00434-0;
RA   Lubert E.J., Sarge K.D.;
RT   "Interaction between protein phosphatase 2A and members of the
RT   importin beta superfamily.";
RL   Biochem. Biophys. Res. Commun. 303:908-913(2003).
RN   [9]
RP   FUNCTION, INTERACTION WITH GNA12, AND SUBCELLULAR LOCATION.
RX   PubMed=15525651; DOI=10.1074/jbc.C400508200;
RA   Zhu D., Kosik K.S., Meigs T.E., Yanamadala V., Denker B.M.;
RT   "Galpha12 directly interacts with PP2A: evidence for Galpha12-
RT   stimulated PP2A phosphatase activity and dephosphorylation of
RT   microtubule-associated protein, tau.";
RL   J. Biol. Chem. 279:54983-54986(2004).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, SUBCELLULAR LOCATION,
RP   AND INTERACTION WITH SGO1.
RX   PubMed=16580887; DOI=10.1016/j.devcel.2006.03.010;
RA   Tang Z., Shu H., Qi W., Mahmood N.A., Mumby M.C., Yu H.;
RT   "PP2A is required for centromeric localization of Sgo1 and proper
RT   chromosome segregation.";
RL   Dev. Cell 10:575-585(2006).
RN   [11]
RP   INTERACTION WITH TP53.
RX   PubMed=17245430; DOI=10.1038/sj.emboj.7601519;
RA   Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.;
RT   "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-
RT   induced dephosphorylation of p53 at Thr55.";
RL   EMBO J. 26:402-411(2007).
RN   [12]
RP   INTERACTION WITH PLA2G16.
RX   PubMed=17374643; DOI=10.1242/jcs.000018;
RA   Nazarenko I., Schafer R., Sers C.;
RT   "Mechanisms of the HRSL3 tumor suppressor function in ovarian
RT   carcinoma cells.";
RL   J. Cell Sci. 120:1393-1404(2007).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   INTERACTION WITH CTTNBP2NL.
RX   PubMed=18782753; DOI=10.1074/mcp.M800266-MCP200;
RA   Goudreault M., D'Ambrosio L.M., Kean M.J., Mullin M.J., Larsen B.G.,
RA   Sanchez A., Chaudhry S., Chen G.I., Sicheri F., Nesvizhskii A.I.,
RA   Aebersold R., Raught B., Gingras A.C.;
RT   "A PP2A phosphatase high density interaction network identifies a
RT   novel striatin-interacting phosphatase and kinase complex linked to
RT   the cerebral cavernous malformation 3 (CCM3) protein.";
RL   Mol. Cell. Proteomics 8:157-171(2009).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-280, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   INVOLVEMENT IN MRD36, AND VARIANT MRD36 LEU-132.
RX   PubMed=25533962; DOI=10.1038/nature14135;
RG   Deciphering Developmental Disorders Study;
RT   "Large-scale discovery of novel genetic causes of developmental
RT   disorders.";
RL   Nature 519:223-228(2015).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
RX   PubMed=9989501; DOI=10.1016/S0092-8674(00)80963-0;
RA   Groves M.R., Hanlon N., Turowski P., Hemmings B.A., Barford D.;
RT   "The structure of the protein phosphatase 2A PR65/A subunit reveals
RT   the conformation of its 15 tandemly repeated HEAT motifs.";
RL   Cell 96:99-110(1999).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 9-589 IN COMPLEX WITH WITH
RP   PPP2CA AND PPME1.
RX   PubMed=18394995; DOI=10.1016/j.cell.2008.02.041;
RA   Xing Y., Li Z., Chen Y., Stock J.B., Jeffrey P.D., Shi Y.;
RT   "Structural mechanism of demethylation and inactivation of protein
RT   phosphatase 2A.";
RL   Cell 133:154-163(2008).
RN   [24]
RP   VARIANTS MRD36 LEU-179; TRP-182 AND HIS-258, AND CHARACTERIZATION
RP   MRD36 OF VARIANTS LEU-179; TRP-182 AND HIS-258.
RX   PubMed=26168268; DOI=10.1172/JCI79860;
RA   Houge G., Haesen D., Vissers L.E., Mehta S., Parker M.J., Wright M.,
RA   Vogt J., McKee S., Tolmie J.L., Cordeiro N., Kleefstra T.,
RA   Willemsen M.H., Reijnders M.R., Berland S., Hayman E., Lahat E.,
RA   Brilstra E.H., van Gassen K.L., Zonneveld-Huijssoon E., de Bie C.I.,
RA   Hoischen A., Eichler E.E., Holdhus R., Steen V.M., Doeskeland S.O.,
RA   Hurles M.E., FitzPatrick D.R., Janssens V.;
RT   "B56delta-related protein phosphatase 2A dysfunction identified in
RT   patients with intellectual disability.";
RL   J. Clin. Invest. 125:3051-3062(2015).
CC   -!- FUNCTION: The PR65 subunit of protein phosphatase 2A serves as a
CC       scaffolding molecule to coordinate the assembly of the catalytic
CC       subunit and a variable regulatory B subunit. Upon interaction with
CC       GNA12 promotes dephosphorylation of microtubule associated protein
CC       TAU/MAPT (PubMed:15525651). Required for proper chromosome
CC       segregation and for centromeric localization of SGO1 in mitosis
CC       (PubMed:16580887). {ECO:0000269|PubMed:15525651,
CC       ECO:0000269|PubMed:16580887}.
CC   -!- SUBUNIT: Found in a complex with at least ARL2, PPP2CB, PPP2R1A,
CC       PPP2R2A, PPP2R5E and TBCD (By similarity). Interacts with FOXO1;
CC       the interaction dephosphorylates FOXO1 on AKT-mediated
CC       phosphorylation sites (By similarity). PP2A consists of a common
CC       heterodimeric core enzyme, composed of PPP2CA a 36 kDa catalytic
CC       subunit (subunit C) and PPP2R1A a 65 kDa constant regulatory
CC       subunit (PR65 or subunit A), that associates with a variety of
CC       regulatory subunits. Proteins that associate with the core dimer
CC       include three families of regulatory subunits B (the
CC       R2/B/PR55/B55, R3/B''/PR72/PR130/PR59 and R5/B'/B56 families), the
CC       48 kDa variable regulatory subunit, viral proteins, and cell
CC       signaling molecules. Interacts with IPO9 (PubMed:12670497).
CC       Interacts with TP53 and SGO1 (PubMed:17245430, PubMed:16580887).
CC       Interacts with PLA2G16; this interaction might decrease PP2A
CC       activity (PubMed:17374643). Interacts with CTTNBP2NL
CC       (PubMed:18782753). Interacts with GNA12; the interaction promotes
CC       protein phosphatase 2A activation causing dephosphorylation of
CC       MAPT (PubMed:15525651). {ECO:0000250|UniProtKB:Q32PI5,
CC       ECO:0000250|UniProtKB:Q76MZ3, ECO:0000269|PubMed:12670497,
CC       ECO:0000269|PubMed:15525651, ECO:0000269|PubMed:16580887,
CC       ECO:0000269|PubMed:17245430, ECO:0000269|PubMed:17374643,
CC       ECO:0000269|PubMed:18394995, ECO:0000269|PubMed:18782753}.
CC   -!- INTERACTION:
CC       P03081:- (xeno); NbExp=3; IntAct=EBI-302388, EBI-1266256;
CC       P31749:AKT1; NbExp=2; IntAct=EBI-302388, EBI-296087;
CC       Q9Y534:CSDC2; NbExp=4; IntAct=EBI-302388, EBI-1763657;
CC       P03129:E7 (xeno); NbExp=3; IntAct=EBI-302388, EBI-866453;
CC       P04020:E7 (xeno); NbExp=2; IntAct=EBI-302388, EBI-7005254;
CC       Q8TCG1:KIAA1524; NbExp=4; IntAct=EBI-302388, EBI-1379376;
CC       P97346:Nxn (xeno); NbExp=2; IntAct=EBI-302388, EBI-309684;
CC       P53816:PLA2G16; NbExp=7; IntAct=EBI-302388, EBI-746318;
CC       P67775:PPP2CA; NbExp=16; IntAct=EBI-302388, EBI-712311;
CC       P30154:PPP2R1B; NbExp=2; IntAct=EBI-302388, EBI-357094;
CC       P63151:PPP2R2A; NbExp=11; IntAct=EBI-302388, EBI-1048931;
CC       Q00005:PPP2R2B; NbExp=6; IntAct=EBI-302388, EBI-1052159;
CC       Q15172:PPP2R5A; NbExp=4; IntAct=EBI-302388, EBI-641666;
CC       Q15173:PPP2R5B; NbExp=3; IntAct=EBI-302388, EBI-1369497;
CC       Q13362:PPP2R5C; NbExp=7; IntAct=EBI-302388, EBI-1266156;
CC       Q13362-1:PPP2R5C; NbExp=5; IntAct=EBI-302388, EBI-1266170;
CC       Q13362-2:PPP2R5C; NbExp=2; IntAct=EBI-302388, EBI-1266173;
CC       Q60996-3:Ppp2r5c (xeno); NbExp=2; IntAct=EBI-302388, EBI-1369292;
CC       Q14738:PPP2R5D; NbExp=9; IntAct=EBI-302388, EBI-396563;
CC       Q16537:PPP2R5E; NbExp=5; IntAct=EBI-302388, EBI-968374;
CC       P60510:PPP4C; NbExp=3; IntAct=EBI-302388, EBI-1046072;
CC       P53041:PPP5C; NbExp=3; IntAct=EBI-302388, EBI-716663;
CC       Q04206:RELA; NbExp=2; IntAct=EBI-302388, EBI-73886;
CC       O43815:STRN; NbExp=6; IntAct=EBI-302388, EBI-1046642;
CC       Q13033-2:STRN3; NbExp=4; IntAct=EBI-302388, EBI-1053876;
CC       P04637:TP53; NbExp=3; IntAct=EBI-302388, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q32PI5}.
CC       Chromosome, centromere {ECO:0000269|PubMed:16580887}. Lateral cell
CC       membrane {ECO:0000269|PubMed:15525651}. Cell projection, dendrite
CC       {ECO:0000269|PubMed:15525651}. Note=Centromeric localization
CC       requires the presence of BUB1. {ECO:0000269|PubMed:16580887}.
CC   -!- DOMAIN: Each HEAT repeat appears to consist of two alpha helices
CC       joined by a hydrophilic region, the intrarepeat loop. The repeat
CC       units may be arranged laterally to form a rod-like structure.
CC   -!- DISEASE: Mental retardation, autosomal dominant 36 (MRD36)
CC       [MIM:616362]: A form of mental retardation, a disorder
CC       characterized by significantly below average general intellectual
CC       functioning associated with impairments in adaptive behavior and
CC       manifested during the developmental period.
CC       {ECO:0000269|PubMed:25533962, ECO:0000269|PubMed:26168268}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the phosphatase 2A regulatory subunit A
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M31786; AAA35531.1; -; mRNA.
DR   EMBL; J02902; AAA36399.1; -; mRNA.
DR   EMBL; CR450340; CAG29336.1; -; mRNA.
DR   EMBL; BC001537; AAH01537.1; -; mRNA.
DR   CCDS; CCDS12849.1; -.
DR   PIR; A34541; A34541.
DR   RefSeq; NP_055040.2; NM_014225.5.
DR   UniGene; Hs.467192; -.
DR   PDB; 1B3U; X-ray; 2.30 A; A/B=2-589.
DR   PDB; 2IE3; X-ray; 2.80 A; A=1-589.
DR   PDB; 2IE4; X-ray; 2.60 A; A=1-589.
DR   PDB; 2NPP; X-ray; 3.30 A; A/D=1-589.
DR   PDB; 2NYL; X-ray; 3.80 A; A/D=8-589.
DR   PDB; 2NYM; X-ray; 3.60 A; A/D=8-589.
DR   PDB; 2PKG; X-ray; 3.30 A; A/B=10-589.
DR   PDB; 3C5W; X-ray; 2.80 A; A=9-589.
DR   PDB; 3DW8; X-ray; 2.85 A; A/D=9-589.
DR   PDB; 3K7V; X-ray; 2.85 A; A=1-589.
DR   PDB; 3K7W; X-ray; 2.96 A; A=1-589.
DR   PDB; 4I5L; X-ray; 2.43 A; A/D=6-589.
DR   PDB; 4I5N; X-ray; 2.80 A; A/D=6-589.
DR   PDB; 4LAC; X-ray; 2.82 A; A=404-589.
DR   PDBsum; 1B3U; -.
DR   PDBsum; 2IE3; -.
DR   PDBsum; 2IE4; -.
DR   PDBsum; 2NPP; -.
DR   PDBsum; 2NYL; -.
DR   PDBsum; 2NYM; -.
DR   PDBsum; 2PKG; -.
DR   PDBsum; 3C5W; -.
DR   PDBsum; 3DW8; -.
DR   PDBsum; 3K7V; -.
DR   PDBsum; 3K7W; -.
DR   PDBsum; 4I5L; -.
DR   PDBsum; 4I5N; -.
DR   PDBsum; 4LAC; -.
DR   ProteinModelPortal; P30153; -.
DR   SMR; P30153; -.
DR   BioGrid; 111510; 272.
DR   DIP; DIP-29394N; -.
DR   IntAct; P30153; 187.
DR   MINT; MINT-1141071; -.
DR   STRING; 9606.ENSP00000324804; -.
DR   iPTMnet; P30153; -.
DR   PhosphoSitePlus; P30153; -.
DR   SwissPalm; P30153; -.
DR   BioMuta; PPP2R1A; -.
DR   DMDM; 143811355; -.
DR   OGP; P30153; -.
DR   REPRODUCTION-2DPAGE; IPI00554737; -.
DR   EPD; P30153; -.
DR   MaxQB; P30153; -.
DR   PaxDb; P30153; -.
DR   PeptideAtlas; P30153; -.
DR   PRIDE; P30153; -.
DR   DNASU; 5518; -.
DR   Ensembl; ENST00000322088; ENSP00000324804; ENSG00000105568.
DR   GeneID; 5518; -.
DR   KEGG; hsa:5518; -.
DR   UCSC; uc002pyp.4; human.
DR   CTD; 5518; -.
DR   DisGeNET; 5518; -.
DR   GeneCards; PPP2R1A; -.
DR   HGNC; HGNC:9302; PPP2R1A.
DR   HPA; CAB018599; -.
DR   MalaCards; PPP2R1A; -.
DR   MIM; 605983; gene.
DR   MIM; 616362; phenotype.
DR   neXtProt; NX_P30153; -.
DR   OpenTargets; ENSG00000105568; -.
DR   PharmGKB; PA33666; -.
DR   eggNOG; KOG0211; Eukaryota.
DR   eggNOG; ENOG410XQVI; LUCA.
DR   GeneTree; ENSGT00730000110944; -.
DR   HOGENOM; HOG000078539; -.
DR   HOVERGEN; HBG000011; -.
DR   InParanoid; P30153; -.
DR   KO; K03456; -.
DR   OMA; MSNILPC; -.
DR   OrthoDB; EOG091G045V; -.
DR   PhylomeDB; P30153; -.
DR   TreeFam; TF105552; -.
DR   BioCyc; MetaCyc:ENSG00000105568-MONOMER; -.
DR   Reactome; R-HSA-113501; Inhibition of replication initiation of damaged DNA by RB1/E2F1.
DR   Reactome; R-HSA-1295596; Spry regulation of FGF signaling.
DR   Reactome; R-HSA-163685; Integration of energy metabolism.
DR   Reactome; R-HSA-163767; PP2A-mediated dephosphorylation of key metabolic factors.
DR   Reactome; R-HSA-180024; DARPP-32 events.
DR   Reactome; R-HSA-195253; Degradation of beta-catenin by the destruction complex.
DR   Reactome; R-HSA-196299; Beta-catenin phosphorylation cascade.
DR   Reactome; R-HSA-198753; ERK/MAPK targets.
DR   Reactome; R-HSA-202670; ERKs are inactivated.
DR   Reactome; R-HSA-2465910; MASTL Facilitates Mitotic Progression.
DR   Reactome; R-HSA-2467813; Separation of Sister Chromatids.
DR   Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion.
DR   Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition.
DR   Reactome; R-HSA-2995383; Initiation of Nuclear Envelope Reformation.
DR   Reactome; R-HSA-380259; Loss of Nlp from mitotic centrosomes.
DR   Reactome; R-HSA-380270; Recruitment of mitotic centrosome proteins and complexes.
DR   Reactome; R-HSA-380284; Loss of proteins required for interphase microtubule organization from the centrosome.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-432142; Platelet sensitization by LDL.
DR   Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane.
DR   Reactome; R-HSA-5339716; Misspliced GSK3beta mutants stabilize beta-catenin.
DR   Reactome; R-HSA-5358747; S33 mutants of beta-catenin aren't phosphorylated.
DR   Reactome; R-HSA-5358749; S37 mutants of beta-catenin aren't phosphorylated.
DR   Reactome; R-HSA-5358751; S45 mutants of beta-catenin aren't phosphorylated.
DR   Reactome; R-HSA-5358752; T41 mutants of beta-catenin aren't phosphorylated.
DR   Reactome; R-HSA-5467337; APC truncation mutants have impaired AXIN binding.
DR   Reactome; R-HSA-5467340; AXIN missense mutants destabilize the destruction complex.
DR   Reactome; R-HSA-5467348; Truncations of AMER1 destabilize the destruction complex.
DR   Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5675221; Negative regulation of MAPK pathway.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-68877; Mitotic Prometaphase.
DR   Reactome; R-HSA-69231; Cyclin D associated events in G1.
DR   Reactome; R-HSA-69273; Cyclin A/B1 associated events during G2/M transition.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   Reactome; R-HSA-8854518; AURKA Activation by TPX2.
DR   Reactome; R-HSA-975957; Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC).
DR   SignaLink; P30153; -.
DR   SIGNOR; P30153; -.
DR   ChiTaRS; PPP2R1A; human.
DR   EvolutionaryTrace; P30153; -.
DR   GeneWiki; PPP2R1A; -.
DR   GenomeRNAi; 5518; -.
DR   PMAP-CutDB; P30153; -.
DR   PRO; PR:P30153; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000105568; -.
DR   CleanEx; HS_PPP2R1A; -.
DR   ExpressionAtlas; P30153; baseline and differential.
DR   Genevisible; P30153; HS.
DR   GO; GO:0000775; C:chromosome, centromeric region; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; NAS:UniProtKB.
DR   GO; GO:0015630; C:microtubule cytoskeleton; NAS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; NAS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; NAS:UniProtKB.
DR   GO; GO:0000159; C:protein phosphatase type 2A complex; IDA:UniProtKB.
DR   GO; GO:0003823; F:antigen binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0019888; F:protein phosphatase regulator activity; TAS:UniProtKB.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0006672; P:ceramide metabolic process; NAS:UniProtKB.
DR   GO; GO:0007059; P:chromosome segregation; IDA:UniProtKB.
DR   GO; GO:0097711; P:ciliary basal body docking; TAS:Reactome.
DR   GO; GO:0007143; P:female meiotic division; IEA:Ensembl.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0000188; P:inactivation of MAPK activity; NAS:UniProtKB.
DR   GO; GO:0051754; P:meiotic sister chromatid cohesion, centromeric; IEA:Ensembl.
DR   GO; GO:0051232; P:meiotic spindle elongation; IEA:Ensembl.
DR   GO; GO:0007084; P:mitotic nuclear envelope reassembly; TAS:Reactome.
DR   GO; GO:0051306; P:mitotic sister chromatid separation; IEA:Ensembl.
DR   GO; GO:0030308; P:negative regulation of cell growth; NAS:UniProtKB.
DR   GO; GO:0042518; P:negative regulation of tyrosine phosphorylation of Stat3 protein; NAS:UniProtKB.
DR   GO; GO:0000184; P:nuclear-transcribed mRNA catabolic process, nonsense-mediated decay; TAS:Reactome.
DR   GO; GO:0070262; P:peptidyl-serine dephosphorylation; IEA:Ensembl.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0006461; P:protein complex assembly; TAS:UniProtKB.
DR   GO; GO:0006470; P:protein dephosphorylation; TAS:UniProtKB.
DR   GO; GO:0030155; P:regulation of cell adhesion; NAS:UniProtKB.
DR   GO; GO:0045595; P:regulation of cell differentiation; NAS:UniProtKB.
DR   GO; GO:0006275; P:regulation of DNA replication; NAS:UniProtKB.
DR   GO; GO:0040008; P:regulation of growth; NAS:UniProtKB.
DR   GO; GO:1903538; P:regulation of meiotic cell cycle process involved in oocyte maturation; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0030111; P:regulation of Wnt signaling pathway; NAS:UniProtKB.
DR   GO; GO:0010033; P:response to organic substance; NAS:UniProtKB.
DR   GO; GO:0008380; P:RNA splicing; NAS:UniProtKB.
DR   GO; GO:0019932; P:second-messenger-mediated signaling; NAS:UniProtKB.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000357; HEAT.
DR   InterPro; IPR021133; HEAT_type_2.
DR   InterPro; IPR031090; PP2A_A_meta.
DR   PANTHER; PTHR10648:SF16; PTHR10648:SF16; 1.
DR   Pfam; PF02985; HEAT; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   PROSITE; PS50077; HEAT_REPEAT; 11.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell membrane; Cell projection; Centromere;
KW   Chromosome; Chromosome partition; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Membrane;
KW   Mental retardation; Reference proteome; Repeat.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000244|PubMed:25944712}.
FT   CHAIN         2    589       Serine/threonine-protein phosphatase 2A
FT                                65 kDa regulatory subunit A alpha
FT                                isoform.
FT                                /FTId=PRO_0000071400.
FT   REPEAT        8     46       HEAT 1.
FT   REPEAT       47     84       HEAT 2.
FT   REPEAT       85    123       HEAT 3.
FT   REPEAT      124    161       HEAT 4.
FT   REPEAT      162    200       HEAT 5.
FT   REPEAT      201    239       HEAT 6.
FT   REPEAT      240    278       HEAT 7.
FT   REPEAT      279    321       HEAT 8.
FT   REPEAT      322    360       HEAT 9.
FT   REPEAT      361    399       HEAT 10.
FT   REPEAT      400    438       HEAT 11.
FT   REPEAT      439    477       HEAT 12.
FT   REPEAT      478    516       HEAT 13.
FT   REPEAT      517    555       HEAT 14.
FT   REPEAT      556    589       HEAT 15.
FT   REGION        8    399       PP2A subunit B binding.
FT   REGION       47    321       Polyoma small and medium T antigens
FT                                Binding.
FT   REGION       85    239       SV40 small T antigen binding.
FT   REGION      400    589       PP2A subunit C binding.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000244|PubMed:25944712}.
FT   MOD_RES     280    280       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   VARIANT     132    132       V -> L (in MRD36).
FT                                {ECO:0000269|PubMed:25533962}.
FT                                /FTId=VAR_073718.
FT   VARIANT     179    179       P -> L (in MRD36; reduces PPP2CA binding;
FT                                reduces PPP2R5A binding; reduces PPP2R5C
FT                                binding; does not affect PPP2R5D binding;
FT                                reduces PPP2R2A binding; reduces PPP2R2B
FT                                binding; does not affect PPP2R3A binding;
FT                                decreases phosphatase activity of PPP2CA;
FT                                dbSNP:rs786205228).
FT                                {ECO:0000269|PubMed:26168268}.
FT                                /FTId=VAR_074488.
FT   VARIANT     182    182       R -> W (in MRD36; reduces PPP2CA binding;
FT                                reduces PPP2R5A binding; reduces PPP2R5C
FT                                binding; does not affect PPP2R5D binding;
FT                                reduces PPP2R2A binding; reduces PPP2R2B
FT                                binding; reduces PPP2R3A binding;
FT                                decreases phosphatase activity of PPP2CA;
FT                                dbSNP:rs786205227).
FT                                {ECO:0000269|PubMed:26168268}.
FT                                /FTId=VAR_074489.
FT   VARIANT     258    258       R -> H (in MRD36; reduces PPP2CA binding;
FT                                reduces PPP2R5A binding; reduces PPP2R5C
FT                                binding; does not affect PPP2R5D binding;
FT                                reduces PPP2R2A binding; reduces PPP2R2B
FT                                binding; reduces PPP2R3A binding; does
FT                                not affect phosphatase activity of
FT                                PPP2CA; dbSNP:rs863225094).
FT                                {ECO:0000269|PubMed:26168268}.
FT                                /FTId=VAR_074490.
FT   CONFLICT    130    130       P -> A (in Ref. 1; AAA35531).
FT                                {ECO:0000305}.
FT   CONFLICT    258    258       R -> A (in Ref. 2; AAA36399).
FT                                {ECO:0000305}.
FT   CONFLICT    272    272       K -> R (in Ref. 6; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    551    551       L -> P (in Ref. 3; CAG29336).
FT                                {ECO:0000305}.
FT   TURN          6      8       {ECO:0000244|PDB:1B3U}.
FT   HELIX        11     19       {ECO:0000244|PDB:1B3U}.
FT   HELIX        25     33       {ECO:0000244|PDB:1B3U}.
FT   HELIX        35     41       {ECO:0000244|PDB:1B3U}.
FT   HELIX        44     49       {ECO:0000244|PDB:1B3U}.
FT   HELIX        51     57       {ECO:0000244|PDB:1B3U}.
FT   HELIX        63     73       {ECO:0000244|PDB:1B3U}.
FT   HELIX        78     80       {ECO:0000244|PDB:1B3U}.
FT   HELIX        83     89       {ECO:0000244|PDB:1B3U}.
FT   HELIX        90     96       {ECO:0000244|PDB:1B3U}.
FT   STRAND       99    101       {ECO:0000244|PDB:2IE4}.
FT   HELIX       102    116       {ECO:0000244|PDB:1B3U}.
FT   HELIX       121    126       {ECO:0000244|PDB:1B3U}.
FT   HELIX       128    136       {ECO:0000244|PDB:1B3U}.
FT   STRAND      138    140       {ECO:0000244|PDB:2PKG}.
FT   HELIX       141    147       {ECO:0000244|PDB:1B3U}.
FT   HELIX       148    150       {ECO:0000244|PDB:1B3U}.
FT   HELIX       151    154       {ECO:0000244|PDB:1B3U}.
FT   TURN        155    157       {ECO:0000244|PDB:1B3U}.
FT   HELIX       160    174       {ECO:0000244|PDB:1B3U}.
FT   HELIX       179    194       {ECO:0000244|PDB:1B3U}.
FT   HELIX       198    203       {ECO:0000244|PDB:1B3U}.
FT   HELIX       205    213       {ECO:0000244|PDB:1B3U}.
FT   HELIX       218    221       {ECO:0000244|PDB:1B3U}.
FT   HELIX       224    234       {ECO:0000244|PDB:1B3U}.
FT   HELIX       237    239       {ECO:0000244|PDB:1B3U}.
FT   HELIX       240    243       {ECO:0000244|PDB:1B3U}.
FT   HELIX       245    252       {ECO:0000244|PDB:1B3U}.
FT   HELIX       257    265       {ECO:0000244|PDB:1B3U}.
FT   HELIX       267    274       {ECO:0000244|PDB:1B3U}.
FT   HELIX       276    281       {ECO:0000244|PDB:1B3U}.
FT   HELIX       283    291       {ECO:0000244|PDB:1B3U}.
FT   HELIX       296    311       {ECO:0000244|PDB:1B3U}.
FT   TURN        315    317       {ECO:0000244|PDB:1B3U}.
FT   HELIX       318    324       {ECO:0000244|PDB:1B3U}.
FT   HELIX       326    334       {ECO:0000244|PDB:1B3U}.
FT   HELIX       339    346       {ECO:0000244|PDB:1B3U}.
FT   HELIX       349    352       {ECO:0000244|PDB:1B3U}.
FT   HELIX       353    356       {ECO:0000244|PDB:1B3U}.
FT   HELIX       358    364       {ECO:0000244|PDB:1B3U}.
FT   HELIX       366    373       {ECO:0000244|PDB:1B3U}.
FT   HELIX       378    385       {ECO:0000244|PDB:1B3U}.
FT   HELIX       389    394       {ECO:0000244|PDB:1B3U}.
FT   HELIX       397    412       {ECO:0000244|PDB:1B3U}.
FT   HELIX       417    434       {ECO:0000244|PDB:1B3U}.
FT   HELIX       436    438       {ECO:0000244|PDB:1B3U}.
FT   HELIX       441    449       {ECO:0000244|PDB:1B3U}.
FT   HELIX       450    452       {ECO:0000244|PDB:1B3U}.
FT   HELIX       456    473       {ECO:0000244|PDB:1B3U}.
FT   HELIX       475    481       {ECO:0000244|PDB:1B3U}.
FT   HELIX       483    488       {ECO:0000244|PDB:1B3U}.
FT   TURN        489    491       {ECO:0000244|PDB:1B3U}.
FT   HELIX       495    520       {ECO:0000244|PDB:1B3U}.
FT   HELIX       522    527       {ECO:0000244|PDB:1B3U}.
FT   HELIX       528    530       {ECO:0000244|PDB:1B3U}.
FT   HELIX       534    547       {ECO:0000244|PDB:1B3U}.
FT   HELIX       548    550       {ECO:0000244|PDB:1B3U}.
FT   HELIX       553    567       {ECO:0000244|PDB:1B3U}.
FT   HELIX       573    585       {ECO:0000244|PDB:1B3U}.
SQ   SEQUENCE   589 AA;  65309 MW;  5174EBE94D537836 CRC64;
     MAAADGDDSL YPIAVLIDEL RNEDVQLRLN SIKKLSTIAL ALGVERTRSE LLPFLTDTIY
     DEDEVLLALA EQLGTFTTLV GGPEYVHCLL PPLESLATVE ETVVRDKAVE SLRAISHEHS
     PSDLEAHFVP LVKRLAGGDW FTSRTSACGL FSVCYPRVSS AVKAELRQYF RNLCSDDTPM
     VRRAAASKLG EFAKVLELDN VKSEIIPMFS NLASDEQDSV RLLAVEACVN IAQLLPQEDL
     EALVMPTLRQ AAEDKSWRVR YMVADKFTEL QKAVGPEITK TDLVPAFQNL MKDCEAEVRA
     AASHKVKEFC ENLSADCREN VIMSQILPCI KELVSDANQH VKSALASVIM GLSPILGKDN
     TIEHLLPLFL AQLKDECPEV RLNIISNLDC VNEVIGIRQL SQSLLPAIVE LAEDAKWRVR
     LAIIEYMPLL AGQLGVEFFD EKLNSLCMAW LVDHVYAIRE AATSNLKKLV EKFGKEWAHA
     TIIPKVLAMS GDPNYLHRMT TLFCINVLSE VCGQDITTKH MLPTVLRMAG DPVANVRFNV
     AKSLQKIGPI LDNSTLQSEV KPILEKLTQD QDVDVKYFAQ EALTVLSLA
//
